Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa.
about
Potential impact of a free online HIV treatment response prediction system for reducing virological failures and drug costs after antiretroviral therapy failure in a resource-limited settingChallenges and opportunities for the implementation of virological testing in resource-limited settingsSwitching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in ThailandHigh-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South AfricaAccounting for variations in ART program sustainability outcomes in health facilities in Uganda: a comparative case study analysisControlling the HIV/AIDS epidemic: current status and global challengesImmunological failure of first-line and switch to second-line antiretroviral therapy among HIV-infected persons in Tanzania: analysis of routinely collected national data.A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi.The Lablite project: a cross-sectional mapping survey of decentralized HIV service provision in Malawi, Uganda and ZimbabweImpact and programmatic implications of routine viral load monitoring in Swaziland.Is CD4 monitoring needed among ugandan clients achieving a virologic and immunologic response to treatment?Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda.Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in NigeriaMonitoring of antiretroviral therapy and mortality in HIV programmes in Malawi, South Africa and Zambia: mathematical modelling studySustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa.Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies.Superior outcomes and lower outpatient costs with scale-up of antiretroviral therapy at the GHESKIO clinic in Port-au-Prince, Haiti.Trends in and determinants of loss to follow up and early mortality in a rapid expansion of the antiretroviral treatment program in Vietnam: findings from 13 outpatient clinicsSAMBA HIV semiquantitative test, a new point-of-care viral-load-monitoring assay for resource-limited settingsDelayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa.Persistent difficulties in switching to second-line ART in sub-saharan Africa--a systematic review and meta-analysis.Clinical evaluation of a low cost, in-house developed real-time RT-PCR human immunodeficiency virus type 1 (HIV-1) quantitation assay for HIV-1 infected patients.Dried blood spots for viral load monitoring in Malawi: feasible and effectiveDurable Suppression of HIV-1 after Virologic Monitoring-Based Antiretroviral Adherence Counseling in Rakai, Uganda.Outcomes of antiretroviral treatment programs in rural Southern Africa.Loss to Followup in HIV-Infected Patients from Asia-Pacific Region: Results from TAHOD.Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trialPredicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithmRates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South AfricaIs There a Need for Viral Load Testing to Assess Treatment Failure in HIV-Infected Patients Who Are about to Change to Tenofovir-Based First-Line Antiretroviral Therapy? Programmatic Findings from Myanmar.Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studiesHIV treatment and care in resource-constrained environments: challenges for the next decade.Implementation and Operational Research: CD4 Count Monitoring Frequency and Risk of CD4 Count Dropping Below 200 Cells Per Cubic Millimeter Among Stable HIV-Infected Patients in New York City, 2007-2013Effect of a clinical decision support system on early action on immunological treatment failure in patients with HIV in Kenya: a cluster randomised controlled trial.Scale-up of Routine Viral Load Testing in Resource-Poor Settings: Current and Future Implementation ChallengesCohort profile: the Themba Lethu Clinical Cohort, Johannesburg, South Africa.Tuberculosis after one year of combination antiretroviral therapy in Nigeria: a retrospective cohort studyComputational models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource-limited settings.Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa: a mathematical modelling analysis.The causal effect of switching to second-line ART in programmes without access to routine viral load monitoring.
P2860
Q21284831-CB9837C4-9354-4710-A38E-24D257AA4D47Q27026923-D1058EDD-F7DA-43AF-B5A9-4D501D31AE3AQ28535141-9E45405C-CFF7-4D0C-A4D7-C01E9A7432B6Q28535483-3B841042-A19B-4329-9411-45AFB0B9FC65Q30380972-7A2FB09A-00A1-41FA-B64D-72EE26B742EFQ30420558-E897C4BE-2888-4575-A90D-1CBE2EE06618Q30911364-B5DD263F-8415-48D9-85DF-06D85AA851DEQ33868639-2CADFD72-6656-44CA-AAD6-6B7651943FE0Q34107634-08505254-2DBA-4894-93FE-286B67AC2A4CQ34110897-BC3F8CB9-09E7-40D3-B4AF-301DF1068152Q34488004-74F44C2A-3C7E-464B-8362-8FC50D5A9C3AQ34523909-B40A352B-FD00-4FC2-87C9-3878238451EAQ34604679-59245662-D702-4452-9AE4-6C87B0331FA6Q34612284-A8DE4409-C2DF-4635-B3BE-0DAAA3717A05Q34625910-6B35C08F-35E4-4C66-A6F5-A7BB9A8DD7BFQ34667707-DB0C95F6-05E1-44E4-B906-FD1AB9CA34F9Q34775595-39C98D90-4BB0-4F25-97D2-D9D175C05AA6Q34996955-7343ED97-7920-455F-8AE2-95FED8FB096EQ35035797-A8497EB1-1C10-4EF1-B10D-2823B33DFC85Q35049762-909A65EA-EF0A-471C-B9B2-88BC8B9C94E5Q35077695-3A48A358-F12F-4C53-A1F4-1AA56286804BQ35112701-30EAB921-F3BB-4A1A-8FAA-66C4F9B2D137Q35515391-1507E38D-C10B-465D-97B3-28F917072F01Q35641893-00EDB73F-D391-4CA5-A535-8AA3D782139DQ35675233-3ACF82A6-1380-4CE3-82A0-B2963D7E8F97Q35810398-5D0AD568-C37D-42A8-8091-48BD600C7EC5Q35965440-06FA9CCA-3C11-448A-B795-01EAF2723B29Q36050916-CA3A7148-30E4-4B2F-9780-16FD438F8E27Q36083869-31C9FDE6-67D5-4A20-9C80-FCFBB4EE4FF2Q36098892-8923058F-BD24-44A5-BCE2-F4FBE954487CQ36204098-06346A98-7C5F-4F0D-9E4C-66582DCDA78EQ36386806-CD651A4B-1C99-44EC-B594-20C8F26A8EB7Q36628401-CE0C334F-5231-4296-944F-EF9E5A275F56Q36649577-5AB1E373-CC9E-4D91-8324-82602429C372Q36715819-4EBA4410-24E0-4CDB-90AE-FA3FF24F41E5Q36749434-E9E0BFF1-7EF3-4F2B-8AB4-568E3A15B054Q36842083-5770DAD1-B5D1-4E62-BF2F-2833237BDFEEQ36844675-3CED1D05-96B4-47CE-A540-BA2C024AE4AFQ37112617-CC3CCDA7-A948-4A45-8CB3-8CC5155D322BQ37137830-9C65B079-044A-4086-AFB6-1A351C01FEF0
P2860
Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Outcomes of antiretroviral tre ...... monitoring in Southern Africa.
@ast
Outcomes of antiretroviral tre ...... monitoring in Southern Africa.
@en
type
label
Outcomes of antiretroviral tre ...... monitoring in Southern Africa.
@ast
Outcomes of antiretroviral tre ...... monitoring in Southern Africa.
@en
prefLabel
Outcomes of antiretroviral tre ...... monitoring in Southern Africa.
@ast
Outcomes of antiretroviral tre ...... monitoring in Southern Africa.
@en
P2093
P2860
P50
P921
P1433
P1476
Outcomes of antiretroviral tre ...... monitoring in Southern Africa
@en
P2093
Benjamin H Chi
IeDEA Southern Africa Collaboration
Nicola Maxwell
Thomas Gsponer
P2860
P304
P356
10.1097/QAD.0B013E328349822F
P407
P50
P577
2011-09-01T00:00:00Z